Table 2.
Clinical studies on collagen.
| Collagen Type | Clinical Condition |
Design | Intervention Duration | Daily Dose | Main Results Reported | Reference |
|---|---|---|---|---|---|---|
| Native collagen |
Osteoarthritis | Randomized single-blind controlled study | 3 months | 40 mg | Symptomatic improvement (WOMAC) | [89] |
| Observational retrospective study | 12 months | 2 mg | Reduce progression of cartilage degradation | [90] | ||
| Randomized double-blind controlled study | 3 months | 40 mg | Symptomatic improvement (WOMAC, VAS) | [91] | ||
| Randomized double-blind placebo-controlled study | 6 months | 40 mg | Symptomatic improvement (WOMAC) | [92] | ||
| Open-label pilot study | 1.5 months | 10 mg | Symptomatic improvement (VAS) | [93] | ||
| Non-interventional, prospective real-life study | 3 months | 40 mg | Symptomatic improvement (WOMAC, VAS) | [94] | ||
| Observational open-label study | 4 months | 40 mg | Symptomatic improvement (WOMAC, VAS) | [95] | ||
| Randomized double-blind placebo-controlled study | 3 months | 40 mg | No significant differences vs. controls | [96] | ||
| Prospective controlled study | 4 months | 40 mg | Symptomatic improvement (WOMAC, VAS) | [97] | ||
| Observational open-label study | 3 months | 40 mg | Symptomatic improvement (WOMAC, VAS) | [98] | ||
| non-Osteoarthritis | Randomized double-blind placebo-controlled study | 4 months | 40 mg | Reduced joint discomfort and increased mobility | [108] | |
| Randomized double-blind placebo-controlled study | 6 months | 40 mg | Reduced joint discomfort and increased mobility | [109,110] | ||
| Hydrolyzed collagen | Osteoarthritis | Randomized double-blind placebo-controlled study | 6 months | 10 g | Increase of proteoglycan content in knee cartilage | [99] |
| Randomized double-blind placebo-controlled study | 6 months | 10 g | Symptomatic improvement (WOMAC, VAS) | [100] | ||
| Randomized single-blind open-labelled controlled study | 6 months | 1.2 g | Symptomatic improvement (WOMAC) | [101] | ||
| Randomized double-blind placebo-controlled study | 3 months | 10 g | Symptomatic improvement (WOMAC, VAS) | [102] | ||
| Randomized double-blind placebo-controlled study | 70 days | 2 g | Symptomatic improvement (WOMAC, VAS) | [103] | ||
| Randomized double-blind controlled study | 3 months | 10 g | Symptomatic improvement (WOMAC, VAS) | [104] | ||
| Prospective observational study | 1 month | 720 mg/360 mg | Symptomatic improvement (WOMAC, VAS) | [105] | ||
| Prospective observational study | 6 months | 1.5 g | Symptomatic improvement (WOMAC, VAS, Lequesne) | [106] | ||
| Randomized double-blind placebo-controlled study | 6 months | 8 g | Symptomatic improvement (WOMAC, VAS) | [107] | ||
| non-Osteoarthritis | Randomized double-blind placebo-controlled study | 3 months | 5 g | Reduction of exercise-induced knee pain | [111] | |
| Randomized double-blind placebo-controlled study | 6 months | 10 g | Reduction of join pain at rest and during activity | [112] | ||
| Randomized double-blind placebo-controlled study | 3 months | 10 g | No significant differences vs. Placebo | [113] |
Abbreviatures: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); Visual Analogue Scale (VAS).